Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

International Clopidogrel Pharmacogenomics Consortium

doi:10.1016/j.ahj.2017.12.010

Scientific article

English

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

ContributorsInternational Clopidogrel Pharmacogenomics Consortium

CollaboratorsReny, Jean-Luc

; Fontana, Pierre

Published inAmerican Heart Journal, vol. 198, p. 152-159

Publication date2018

Abstract

The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet inhibition by clopidogrel shows wide interpatient variability, and high on-treatment platelet reactivity is a risk factor for atherothrombotic events, particularly in high-risk populations. CYP2C19 polymorphism plays an important role in this variability, but heritability estimates suggest that additional genetic variants remain unidentified. The aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify genetic determinants of clopidogrel pharmacodynamics and clinical response.

Keywords

Acute Coronary Syndrome/diagnosis/drug therapy/mortality
Aged
Clopidogrel/therapeutic use
Female
Genetic Association Studies
Genome-Wide Association Study
Humans
Internationality
Male
Middle Aged
Molecular Targeted Therapy/methods
Pharmacogenetics
Prognosis
Receptors
Purinergic P2Y12/drug effects/genetics
Risk Assessment
Survival Rate
Treatment Outcome

Affiliation entities

Research groups

Plaquettes et antithrombotiques (13)

Citation (ISO format)

International Clopidogrel Pharmacogenomics Consortium. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). In: American Heart Journal, 2018, vol. 198, p. 152–159. doi: 10.1016/j.ahj.2017.12.010

Article (Published version)

Article (Accepted version)

Identifiers

PID : unige:116553
DOI : 10.1016/j.ahj.2017.12.010
PMID : 29653637

Journal ISSN0002-8703

453views

143downloads

Creation15/03/2019 10:11:00

First validation15/03/2019 10:11:00

Update time03/02/2025 11:22:21

Status update03/02/2025 11:22:21

Last indexation03/02/2025 11:30:32

Archive ouverte UNIGE

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

Technical informations